Company intelligence / Profile preview
Regen BioPharma, Inc.
La Mesa, California, United Statesregenbiopharmainc.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Preclinical
01
Overview
Regen BioPharma has a diverse pre-clinical pipeline focused on modulating immune checkpoints such as NR2F6 for cancer and autoimmune diseases. The company utilizes autologous cell therapies, RNA/DNA therapeutics, small molecules, and proprietary platforms like KimerApt aptamers and DuraCAR CAR-T cells. No late-stage or commercialized products are reported as of now[1][4][5].
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Autologous cell therapiesRNA-based immunotherapy (including siRNA and shRNA)DNA-based immunotherapy (aptamers)Small molecules
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Beyond the preview
Go deeper on Regen BioPharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regen BioPharma, Inc..